Keywords: GlaxoSmithKline, ChemoCentryx, Traficet-EN, Inflammatory bowel syndrome, Crohn's disease

GlaxoSmithKline exercises option for ChemoCentryx’ Traficet-EN for IBD

Article | 12 January 2010

As part of a deal signed in 2006, UK drug giant GlaxoSmithKline has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease, licensed from USA-based ChemoCentryx.

T Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.

30 day FREE trial

Sign up in less than 60 seconds! No payment needed.

Want to read the full article?
Take a 30 day FREE Trial

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in